Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tucson, Arizona 85724


Purpose:

Evaluate the feasibility of translating preclinical Chemical Exchange Saturation Transfer (CEST) MRI protocol designed to estimate tumor extracellular pH (pHe) to a clinical MRI scanner in women with early stage breast cancer. Assays are used to quantify tumor acidosis.


Study summary:

Those involved in the treatment of patients with breast cancer have pioneered the field of personalized cancer therapy through the use of targeted therapies and their associated biomarkers. Assays to quantify tumor acidosis and hypoxia are hypothesized to potentially represent such biomarkers. However there is currently no gold standard for measuring either. This trial will evaluate the feasibility of translating preclinical Chemical Exchange Saturation Transfer (CEST) MRI protocol designed to estimate tumor extracellular pH (pHe), to a clinical MRI scanner in women with early stage breast cancer. This trial will generate preliminary data regarding the feasibility of this imaging technique. If successful, in future studies CEST MRI may serve as an imaging biomarker for acidosis and hypoxia.


Criteria:

Inclusion Criteria: - Newly diagnosed infiltrating ductal carcinoma (IDC) of the breast - >= 1.0 cm primary tumor - Calculated creatinine clearance >= 50 mL/min - Willing and able to provide informed consent - Age ≥ 18 years - ECOG performance status 0-2 - Informed of the investigational nature of this study Exclusion Criteria: - Allergy to iodinated contrast agent - Use of metformin, aminoglycosides, other nephrotoxic medications, or daily use of NSAIDs - Diabetes mellitus - History of severe claustrophobia - Presence of electrically, magnetically, or mechanically activated implants including cardiac pacemakers, cochlear implants, magnetic surgical clips or prosthesis that would preclude MRI - Use of > 1 antihypertensive drug - Pregnancy or breastfeeding - Paraproteinemia syndromes or multiple myeloma - Collagen vascular disease - Active hyperthyroidism - Active pharmaceutical treatments for cancer


NCT ID:

NCT02380209


Primary Contact:

Principal Investigator
Pavani Chalasani, MD
University of Arizona


Backup Contact:

N/A


Location Contact:

Tucson, Arizona 85724
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.